WO2005086638A3 - Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof - Google Patents

Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof Download PDF

Info

Publication number
WO2005086638A3
WO2005086638A3 PCT/US2005/004759 US2005004759W WO2005086638A3 WO 2005086638 A3 WO2005086638 A3 WO 2005086638A3 US 2005004759 W US2005004759 W US 2005004759W WO 2005086638 A3 WO2005086638 A3 WO 2005086638A3
Authority
WO
WIPO (PCT)
Prior art keywords
making
methods
cell proliferation
analogs
exhibiting inhibition
Prior art date
Application number
PCT/US2005/004759
Other languages
French (fr)
Other versions
WO2005086638A2 (en
Inventor
Duane D Miller
James T Dalton
Veeresa Gududuru
Eunju Hurh
Original Assignee
Univ Ohio State Res Found
Duane D Miller
James T Dalton
Veeresa Gududuru
Eunju Hurh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ohio State Res Found, Duane D Miller, James T Dalton, Veeresa Gududuru, Eunju Hurh filed Critical Univ Ohio State Res Found
Priority to AU2005220705A priority Critical patent/AU2005220705A1/en
Priority to EP05749117A priority patent/EP1723127A4/en
Priority to CA002559333A priority patent/CA2559333A1/en
Priority to EA200601471A priority patent/EA200601471A1/en
Priority to JP2006553347A priority patent/JP2007522247A/en
Priority to BRPI0507612-9A priority patent/BRPI0507612A/en
Publication of WO2005086638A2 publication Critical patent/WO2005086638A2/en
Publication of WO2005086638A3 publication Critical patent/WO2005086638A3/en
Priority to IL177444A priority patent/IL177444A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Analogs exhibiting inhibition of cell proliferation are provided. Methods of making the analogs are also included. The analogs can be used to treat cancerous conditions such as prostate, breast, and ovarian cancer.
PCT/US2005/004759 2004-02-11 2005-02-11 Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof WO2005086638A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2005220705A AU2005220705A1 (en) 2004-02-11 2005-02-11 Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof
EP05749117A EP1723127A4 (en) 2004-02-11 2005-02-11 Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof
CA002559333A CA2559333A1 (en) 2004-02-11 2005-02-11 Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof
EA200601471A EA200601471A1 (en) 2004-02-11 2005-02-11 CELL CELL PROLIFERATION INHIBITORS (OPTIONS), PHARMACEUTICAL COMPOSITION ON THEIR BASIS, METHOD OF DESTROYING CANCER CELLS (VARIANTS) AND METHOD OF TREATMENT AND PREVENTION OF MALANCES AND PREVENTION OF HUMAN MEDICINES
JP2006553347A JP2007522247A (en) 2004-02-11 2005-02-11 Analogs showing inhibition of cell proliferation, methods of making them and uses thereof
BRPI0507612-9A BRPI0507612A (en) 2004-02-11 2005-02-11 analogues exhibiting inhibition of cell proliferation and methods for making and using these
IL177444A IL177444A0 (en) 2004-02-11 2006-08-10 Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54372404P 2004-02-11 2004-02-11
US60/543,724 2004-02-11
US55580304P 2004-03-24 2004-03-24
US60/555,803 2004-03-24

Publications (2)

Publication Number Publication Date
WO2005086638A2 WO2005086638A2 (en) 2005-09-22
WO2005086638A3 true WO2005086638A3 (en) 2005-11-24

Family

ID=34976061

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/004759 WO2005086638A2 (en) 2004-02-11 2005-02-11 Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof

Country Status (8)

Country Link
EP (1) EP1723127A4 (en)
JP (1) JP2007522247A (en)
AU (1) AU2005220705A1 (en)
BR (1) BRPI0507612A (en)
CA (1) CA2559333A1 (en)
EA (1) EA200601471A1 (en)
IL (1) IL177444A0 (en)
WO (1) WO2005086638A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101395146B1 (en) * 2011-02-09 2014-05-16 부산대학교 산학협력단 New compounds having skin whitening, antioxidant and PPAR activity, and medical use thereof
WO2014066613A2 (en) * 2012-10-26 2014-05-01 Zhejiang University Sphingolipid metabolite mimetics
CA2909510C (en) * 2013-03-15 2024-04-02 Cancer Research Technology, Llc Methods and compositions for gamma-glutamyl cycle modulation
WO2023170024A1 (en) * 2022-03-11 2023-09-14 University Of Copenhagen Camk2 modulators and their use in medicine
CN115894398B (en) * 2022-12-02 2024-03-12 青岛科技大学 Fluothiazole amide-containing insecticidal acaricide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962096A (en) * 1987-03-24 1990-10-09 Nippon Chemiphar Co., Ltd. Heterocyclic glycerol derivatives and their use as anti-hypertensive agents
US4826990A (en) * 1987-09-30 1989-05-02 American Home Products Corporation 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US5149704A (en) * 1991-05-03 1992-09-22 Abbott Laboratories Platelet activating antagonists
FR2678938B1 (en) * 1991-07-10 1993-10-08 Rhone Poulenc Rorer Sa PYRROLIDINE DERIVATIVES, THEIR PREPARATION AND THE MEDICINAL PRODUCTS CONTAINING THEM.
FR2700168B1 (en) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Thiazolidine derivatives, their preparation and the drugs containing them.
DE19546918A1 (en) * 1995-12-15 1997-06-19 Bayer Ag Bicyclic heterocycles

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DALTON TRANSACTIONS, vol. 18, 2004, pages 2855 - 2866 *
DATABASE CAPLUS [online] SZABO P. ET AL: "Electron impact mass spectrometry of 2-aryl-thiazolidine-4-carboxylic acids.", XP002991574, Database accession no. (1996:441099) *
DATABASE CAPLUS PESSOA J. ET AL.: "N-Salicylideneamino acidato complexes of oxovanadium (IV).The cysteine and penicillamine complexes.", XP002991575 *
RAPID COMMUNICATIONS IN MAAS SPECTROMETRY, vol. 10, no. 9, 1996, pages 1136 - 1140 *

Also Published As

Publication number Publication date
BRPI0507612A (en) 2007-07-03
EP1723127A2 (en) 2006-11-22
IL177444A0 (en) 2006-12-10
EA200601471A1 (en) 2007-10-26
EP1723127A4 (en) 2009-10-28
AU2005220705A1 (en) 2005-09-22
CA2559333A1 (en) 2005-09-22
JP2007522247A (en) 2007-08-09
WO2005086638A2 (en) 2005-09-22

Similar Documents

Publication Publication Date Title
HK1217103A1 (en) Diarylhydantoin compounds
WO2007127010A3 (en) Diarylthiohydantoin compounds
MY160399A (en) Compounds, compositions, and methods for preventing metastasis of cancer cells
WO2011087845A3 (en) Metabolomic profiling of prostate cancer
WO2007024496A3 (en) Compositions and methods for treating prostate disorders
WO2014059238A8 (en) Modulation of androgen receptor expression
HK1108284A1 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
MX2010000465A (en) Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders.
WO2008089397A3 (en) Adrb2 cancer markers
WO2008134474A3 (en) Compositions and methods including cell death inducers and procaspase activation
EA200901074A1 (en) TREATMENT OF THE METASTATIC STAGE OF PROSTATE CANCER WITH DEGARELIX
WO2011083090A3 (en) Methods for treating breast cancer
NZ579478A (en) Epha3 antibodies for the treatment of solid tumors
WO2007100920A3 (en) Diagnosis and treatment of prostate cancer
WO2005086638A3 (en) Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof
MX2010005324A (en) Compositions and methods for inhibiting tumor progression.
WO2008092002A3 (en) Compositions and methods for treating and diagnosing pancreatic cancer
WO2018193476A3 (en) Anticancer compounds
WO2007047803A3 (en) Use of prolactin in the prophylactic treatment of cancer
WO2010121226A3 (en) Anticancer agents
WO2007012430A8 (en) Method for induction and enhancement of apoptosis in tumor cells
WO2009028968A8 (en) Cell marker of melanocyte cell lineage and uses thereof
WO2008153091A1 (en) Screening method
WO2008009895A3 (en) Matriptase-2

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2006553347

Country of ref document: JP

Ref document number: 177444

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/009242

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005749117

Country of ref document: EP

Ref document number: 2559333

Country of ref document: CA

Ref document number: 549789

Country of ref document: NZ

Ref document number: 2005220705

Country of ref document: AU

Ref document number: 3280/CHENP/2006

Country of ref document: IN

Ref document number: 200601471

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2005220705

Country of ref document: AU

Date of ref document: 20050211

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005220705

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580012040.7

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005749117

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0507612

Country of ref document: BR

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)